Find Academic Supervisors

• Clinical Sciences
• Cardiorespiratory Medicine and Haematology
• Biochemistry and Cell Biology
• +3 more

Graeme Birdsey is an Associate Professor in Vascular Science at the National Heart & Lung Institute, part of Imperial College London's Faculty of Medicine. His research focuses on transcriptional and epigenetic regulation of endothelial cell gene expression in angiogenesis and lymphangiogenesis. He has held affiliations with the CDT in Chemical Biology, the Institute of Chemical Biology, the Stem Cell Regenerative Medicine Network, and the Vascular Science Network. Dr. Birdsey earned a BSc in Applied Biochemistry from Liverpool John Moores University and a PhD in Molecular Cell Biology from University College London (UCL). His postdoctoral training included work in Prof. Chris Danpure's lab (UCL) on alanine:glyoxylate aminotransferase (AGT) targeting, followed by studies on nitric oxide regulation under Prof. Patrick Vallance at UCL. His research spans vascular biology, with emphasis on ERG transcription factor roles in endothelial cell function, vascular inflammation, and disease mechanisms. Key areas include lymphatic malformations, cardiovascular diseases, and genetic syndromes linked to ERG mutations. His work integrates molecular biology, genomics, and 3D modeling approaches. Publications highlight contributions to vascular biology, including ERG's role in angiogenesis regulation, therapeutic strategies using ultrasound-microbubble systems, and genetic insights into rare diseases. His research bridges basic science and clinical applications in cardiovascular and inflammatory disorders.

• Breast Cancer
• Ovarian Cancer
• Genetic Counseling
• +3 more

Niklas Loman is an Associate Professor and Principal Investigator at the Lund University Cancer Centre (LUCC), affiliated with Lund University. His primary roles include Consultant, Project Manager, and Supervisor in breast/ovarian cancer research. Research Focus: Loman’s work centers on breast and ovarian cancer, particularly BRCA1/2 mutations, genetic testing, immunometabolism dynamics, and clinical trial design. His contributions include the Sweden Cancerome Analysis Network-Breast (SCAN-B) initiative, a large-scale genomic analysis platform, and the NordicTrip phase III trial exploring chemotherapy combinations for triple-negative breast cancer. Publications & Projects: With 127 publications, his recent work includes studies on estrogen receptor-low breast cancers, longitudinal immunometabolic profiling, and genetic testing guidelines. Active projects include NordicTrip (2024–2029) and SCAN-B (since 2009), focusing on genomic insights and clinical implementation. Awards & Recognition: While no specific awards are listed, his contributions to breast cancer genomics and clinical trials reflect significant academic impact. Grants & Teams: Funded by Cancerfonden and Mrs. Berta Kamprad’s Cancer Foundation, Loman collaborates on translational research and organizes events like the LUCC Breast Retreat and seminars on HER2-positive/triple-negative cancers.

• Hematology
• Molecular Biology
• Genomics
• +3 more

Sólja Frida Remisdóttir Veyhe is a visiting researcher at the University of Southern Denmark , affiliated with the Faculty of Health Sciences and the Department of Clinical Research within the Research Unit of Haematology (Odense) . Her work focuses on chronic lymphocytic leukemia (CLL) and molecular responses to ibrutinib therapy. Education: MSc in Biochemistry and Molecular Biology (June 2019) Her research integrates multi-omics approaches to study CLL progression, ibrutinib resistance mechanisms, and B cell dynamics. Key methodologies include genomic profiling, transcriptomics, and longitudinal patient analysis. Recent publications highlight her contributions to understanding low allelic burden BTK mutations in ibrutinib resistance and developing multi-omics frameworks for treatment response evaluation. Committee Membership: Member of the Clinical Institute Council at SDU (2021–2024)

• Hematology
• Oncology
• Genetics
• +3 more

Marcus Høy Hansen is a researcher at the Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, and affiliated with the Research Unit of Haematology (Odense). His work focuses on hematology, oncology, and genomic analysis of blood cancers. Research interests include: Molecular mechanisms in B-cell malignancies Multi-omics approaches to treatment response evaluation Somatic mutation detection using liquid biopsy Targeted sequencing for risk stratification in lymphomas His recent publications analyze: Longitudinal ibrutinib response in chronic lymphocytic leukemia Comparative mutation detection in non-Hodgkin lymphoma MYC/BCL2 aberrations in diffuse large B-cell lymphoma Genomic overlap between myeloproliferative neoplasms and lymphoma Labs & teams: Research Unit of Haematology (Odense) collaborating with Odense University Hospital (OUH) and Karolinska Institutet (KI).

• Biochemistry
• Genetics
• Molecular Biology
• +5 more

Gitte Hoffmann Bruun is a researcher at the Department of Biochemistry and Molecular Biology, University of Southern Denmark, specializing in translational biology. Her work bridges genetic research and molecular medicine, focusing on RNA splicing mechanisms and genetic susceptibility to diseases. Research Interests: Biochemistry, Genetics, Molecular Biology, RNA Splicing, Exome Sequencing, and Genetic Susceptibility. Bruun's research leverages advanced bioinformatics and molecular biology techniques, such as deep learning models for predicting protein-RNA binding effects and exome sequencing to identify disease-related genes. Her work has applications in developing allele-specific therapies and antisense oligonucleotide-based treatments. Her publications and patents highlight a strong emphasis on splice switching oligonucleotides, pseudoexon targeting, and Mycobacterial infection genetics. These contributions underscore her role in translational research linking computational biology to clinical applications.

• Horticultural Crop Improvement
• Genetic Transformation
• Gene Editing
• +5 more

Guo-Qing Song is a Professor and Associate Director of the Plant Biotechnology Resource & Outreach Center at Michigan State University 's Department of Horticulture. With over 15 years of faculty experience at MSU, his work integrates genetic transformation , gene editing , and biotechnology to improve horticultural crops like blueberry, grape, and cherry. Joined MSU in 2007 Appointment: 15% Teaching, 30% Research, 50% Outreach Previously: Research Associate at MSU (2002-2007) and Mitsui Chemical (2000-2002) Research Interests focus on: Basic Research : Molecular basis of chilling-mediated flowering in woody plants, MADS-box K-domain applications for yield, VcFT/SOC1 genes in blueberry flowering, and phytohormone interactions . Applied Research : Developing GM crops for abiotic tolerance (cold/heat/drought), transgrafting with siRNAs, and stable transformation systems for 30+ plant species. His scientific contributions include: Over 50 peer-reviewed publications (2004-present) Key patents on K-domain technology and transgrafting Recipient of the Outstanding International Horticulturalist Award (2024) Co-developer of CRISPR-Cas9 protocols for woody plants Outreach constitutes 50% of his appointment, focusing on: Training in plant transformation and gene editing Technical support for biotechnology adoption in specialty crops Developing micropropagation systems for fruit crops

Nicholas ZorkoView profile

Assistant Professor

• Prostate Cancer
• Immunotherapy
• Natural Killer (NK) Cell Therapy
• +4 more

Nicholas Zorko, MD, PhD, is an Assistant Professor of Medicine at the University of Minnesota. His work centers on advancing NK cell-based immunotherapies for prostate and other solid tumors, with a focus on B7-H3 and PSMA-targeted tri-specific killer engagers (TriKEs). Research Interests Targeting B7-H3 and PSMA in prostate cancer immunotherapy Enhancing NK cell function in "cold" tumor microenvironments Development of off-the-shelf CAR NK cell therapies Investigating HLA class I expression and immune evasion mechanisms Scientific Contributions The 15 most recent publications (2025-2023) demonstrate expertise in tumor immunology, tri-specific antibody engineering, and pan-cancer therapeutic strategies. Key trends include optimizing radioligand therapy for prostate cancer, characterizing immune cell infiltration in solid tumors, and addressing adverse events in T-cell and NK cell therapies.

• Human T Cell Immune Responses
• HLA Molecules
• HIV Vaccine Development
• +4 more

Professor Andrew McMichael is a distinguished academic in the Nuffield Department of Medicine at the University of Oxford . With over 50 years of experience in immunology, he has been pivotal in elucidating T cell immune responses, particularly focusing on HLA-restricted CD8 T cells and their role in HIV infection and vaccination strategies. Professor of Molecular Medicine Member of Nuffield Department of Medicine Collaborator with OHSU's Louis Picker His research spans three decades, transitioning from influenza to HIV studies, and currently centers on HLA-E restricted immune responses and their potential in universal immunotherapies. Key areas include: Analysis of early immune responses in HIV infection Investigation of viral escape mechanisms through epitope mutation Development of CMV-vectored SIV vaccines with HLA-E restricted T cells Structural studies of HLA-E-peptide complexes using crystallography and SAXS Exploration of non-classical HLA molecules in immune regulation Translational approaches to harness cellular immunity for vaccine design Publications highlight his team's work on HLA-E ligand diversity , NK cell modulation , and HLA-B*27 autoimmunity connections. Collaborations with Adrian Hill, Sarah Gilbert, and Tomas Hanke demonstrate his integrative approach to medical science. His laboratory continues to pioneer research on virus-specific and tumor-specific HLA-E restricted T cells , aiming to develop broadly applicable immunotherapies due to HLA-E's limited polymorphism.

• Medical Genetics
• Ophthalmology
• Genomics
• +6 more

Professor Kathryn Burdon is Deputy Director of the Menzies Institute for Medical Research at the University of Tasmania. She holds a Professorial Research Fellowship and leads the Genetics and Cancer Theme. Her research focuses on identifying genetic factors underlying eye diseases such as glaucoma, cataracts, and keratoconus, with a particular emphasis on pediatric cases. She also investigates genetic contributions to multiple sclerosis and cardiovascular conditions. Education: PhD (2004) in pediatric cataract genetics from University of Tasmania; BSc(Hons) in albinism genetics (1999). Postdoctoral training at Wake Forest University. Research Interests Gene discovery for blinding eye diseases using whole genome sequencing and supercomputing analysis Role of genetic and environmental factors in treatment response (e.g., anti-VEGF therapy for macular degeneration) Utilization of the Tasmanian Ophthalmic Biobank and population records for genetic studies Development of zebrafish models to study disease mechanisms Article Trends Recent work focuses on pediatric cataract genetics, diabetic maculopathy GWAS, and polygenic risk scores for glaucoma. Emphasis on translating genetic findings into clinical care through predictive testing and personalized therapies. Awards Menzies Institute Academic Mentoring Award (2022) NHMRC Fellowships (Peter Doherty, Senior Research) Invited lectures at major ophthalmology and genetics conferences Grants & Supervision $2M+ in NHMRC and international grants for gene discovery projects Supervised over 20 PhD/Masters students on topics like EBV-MS links and pediatric cataract genetics Labs & Collaborations Leads the Tasmanian Ophthalmic Biobank and collaborates with global groups (Flinders University, Harvard, University of Melbourne) on multi-ethnic genetic studies.

• Molecular plant pathology
• Proteomics
• Metabolomics
• +3 more

Associate Professor Kar-Chun Tan is affiliated with Curtin University's School of Molecular and Life Sciences within the Faculty of Science and Engineering. He leads the 'Septoria nodorum blotch biology' research program at the Centre for Crop Disease Management (CCDM). His work focuses on molecular plant pathology, proteomics, metabolomics, and genetic mapping of wheat to combat fungal pathogens. Key research areas include necrotrophic effector identification, transcription factor regulation of virulence, and wheat defensome mechanisms. Dr. Tan has received significant recognition, including a 2014 Eureka Prize finalist award for Sustainable Agriculture and a 2005 Western Australian Young Achiever Award semifinalist nomination. His research has led to advancements in understanding fungal pathogen interactions with wheat, including the role of transcription factors like PnPf2 in effector gene expression. His publications span proteomic analyses of oomycetes, transcriptional regulation in fungal pathogens, and genetic mapping of wheat resistance genes. Collaborative projects include studies on Septoria nodorum blotch dynamics, phosphite action mechanisms in oomycetes, and the role of accessory chromosomes in pathogen virulence. Tan's work bridges molecular biology and agricultural applications, aiming to enhance crop resilience against fungal diseases.

• Proteomics
• Bioinformatics
• Cancer Research
• +4 more

Yun-ping Zhu is a prominent professor in proteomics and bioinformatics at the Chinese Academy of Medical Sciences, School of Basic Medical Sciences. With 173 publications, an h-index of 37, and over 6,654 citations, Dr. Zhu has established significant expertise in proteomics infrastructure development, cancer research, and multi-omics integration methods. Dr. Zhu's research focuses on proteomics data management systems including iProX and ProteomeXchange consortium contributions, cancer subtype analysis using advanced computational approaches like MoGCN, and protein interaction networks with applications in clinical diagnostics. Their work bridges computational biology with practical medical applications, particularly in liver cancer and other malignancies. The publication record spanning from 2004 to 2022 demonstrates consistent research productivity with notable contributions to large-scale proteomics data standards and infrastructure. Recent work has focused on multi-omics integration methods for cancer subtype classification and improving data management practices for clinical proteomics. Dr. Zhu maintains extensive collaborations, particularly with F. He (a senior researcher with 451 publications), reflecting strong integration within the Chinese proteomics research community and international consortia.

Julia CarnevaleView profile

Physician Scientist

• Gastrointestinal Oncology
• Cancer Immunotherapy
• CRISPR Engineering
• +3 more

Dr. Julia Carnevale is a physician-scientist at the University of California San Francisco (UCSF), specializing in gastrointestinal oncology and cancer immunotherapy. Her research focuses on engineering more potent T cell therapies for cancer treatment using CRISPR technology and molecular profiling to overcome tumor microenvironment suppression.

Melike PekmezciView profile

Assistant Clinical Professor

• Neuropathology
• Ocular Pathology
• Molecular Oncology
• +3 more

Dr. Melike Pekmezci is a clinical pathologist at the University of California San Francisco (UCSF) School of Medicine, Department of Pathology , specializing in tumors and abnormalities of the central nervous system and ocular tissues. Education: M.D., Hacettepe University Faculty of Medicine (2004) Ophthalmology Residency, Gazi University (2007) Pathology Residency, Loyola University Medical Center (2011) Pathology Residency & Fellowships, UCSF (2012–2016) Research Focus: Molecular classification of brain and eye tumors Identification of diagnostic/prognostic biomarkers Integration of genetic and epigenetic profiling in tumor management Collaborative studies on neurofibromatosis and gliomas Scientific Contributions: Over 75 peer-reviewed publications, including key studies on CNS angiocentric tumors, glioma evolution, and immunotherapy applications. Active in developing AI-driven diagnostic models for glioma detection. Professional Affiliations: United States & Canadian Academy of Pathology American Association of Neuropathologists Verhoeff-Zimmerman Society American Association of Ophthalmic Oncologists and Pathologists

• Breast Cancer
• Cancer Epidemiology
• Molecular Oncology
• +3 more

Christopher Godina is a Postdoctoral Fellow at Lund University Cancer Center (LUCC) within the Faculty of Medicine at Lund University. His research focuses on cancer epidemiology and radiation, with a specific emphasis on breast cancer biology and molecular mechanisms. Position: Postdoctoral Fellow, Cancer Epidemiology & Radiation Institution: Lund University Cancer Center (LUCC) University: Lund University, Faculty of Medicine Email: christopher.godina@med.lu.se ORCID: 0000-0003-1501-0458 Dr. Godina's expertise spans multiple research areas including Breast Cancer (100%), Caveolin-1 (50%), Patient outcomes (42%), Prospective Cohort Studies (33%), Insulin-Like Growth Factor-Binding Proteins (33%), Therapeutic Procedures (30%), Messenger RNA expression (23%), and Contralateral cancer development (21%). His work contributes to UN Sustainable Development Goal 3: Good Health and Well-being. Analysis of Dr. Godina's publication record reveals a strong focus on molecular biomarkers in breast cancer, particularly examining Caveolin-1 expression patterns, insulin-like growth factor binding proteins (especially IGFBP7), and their clinical implications. His research spans from basic molecular mechanisms to clinical applications, with studies investigating how these biomarkers can improve risk prediction, prognosis, and treatment selection for breast cancer patients. Notably, his work published in Cell on PCSK9 germline variants driving breast cancer metastasis via LRP1 receptor demonstrates significant impact in the field. Highly cited work in Cell (2024) with 11 citation indexes and 28 Mendeley readers Multiple publications in high-impact journals including Carcinogenesis, Scientific Reports, and NPJ Precision Oncology Research focuses on translating molecular findings to clinical applications Dr. Godina actively participates in the Lund University Cancer Centre research community, having presented his work at LUCC meetings. His collaborative research involves multiple investigators at Lund University and potentially international partners, as evidenced by his multi-authored publications across various high-impact journals.

Kathryn GravesView profile

Associate Professor

• Equine Genetics
• Canine Hereditary Diseases
• Molecular Diagnostics
• +4 more

Kathryn Graves serves as Associate Professor and Director of Genetic Testing within the Department of Veterinary Science at the University of Kentucky's Martin-Gatton College of Agriculture, Food and Environment. Based at the Gluck Equine Research Center, her work bridges equine and canine genetics with direct clinical applications. Her research focuses on equine genetic disorders including epidermolysis bullosa in American Saddlebreds and ACAN dwarfism, alongside canine hereditary cataracts in Boston Terriers. Using advanced genomic techniques like whole genome sequencing and qPCR assay development, her laboratory identifies causative mutations and develops diagnostic tools for breeders and veterinarians. Recent publications reveal strong trends in molecular diagnostic development (2022 qPCR assay for equine arteritis virus carriers) and population genomics (2013 studies on modern horse diversity). Her work consistently connects basic genetic discoveries to practical veterinary applications, particularly in equine reproductive health and inherited disorders. As Principal Investigator on three AKC Canine Health Foundation grants (2002-2022), she has led significant projects on Boston Terrier cataracts and canine genetic markers. Her research program demonstrates sustained funding success with longitudinal focus on hereditary disease mechanisms. Dr. Graves' laboratory operates within the Gluck Equine Research Center's Genetic Testing Lab, providing specialized diagnostic services while advancing fundamental understanding of genetic disorders in performance horses and companion animals. Her collaborative approach is evident in multi-institutional publications involving veterinary diagnostic laboratories and equine research centers globally.